Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Fleischer

Showing results (241-250 of 257) with videos related to

Pageof 26
Sort By:
The Journal of Allergy and Clinical Immunology. in Practice|March 1, 2025
Long-Term Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: An Open-Label Active Treatment (REALISE Study)Jacqueline A Pongracic, Rémi Gagnon, Gordon Sussman, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 1, 2021
Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial ResultsJacqueline A Pongracic, Rémi Gagnon, Gordon Sussman, et al.
The Journal of Allergy and Clinical Immunology|July 14, 2020
Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year resultsDavid M Fleischer, Wayne G Shreffler, Dianne E Campbell, et al.
Clinical and Translational Allergy|November 7, 2024
GA<sup>2</sup>LEN ANACARE consensus statement: Potential of omalizumab in food allergy managementTorsten Zuberbier, Antonella Muraro, Ulugbek Nurmatov, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 16, 2025
Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPEMatthew Greenhawt, Deborah Albright, Sara Anvari, et al.
Clinical and Translational Allergy|November 29, 2024
10 practical priorities to prevent and manage serious allergic reactions: GA<sup>2</sup>LEN ANACare and EFA Anaphylaxis ManifestoAntonella Muraro, Debra de Silva, Marcia Podesta, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 21, 2021
The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus ApproachMatthew Greenhawt, Elissa M Abrams, Marcus Shaker, et al.
The New England Journal of Medicine|May 10, 2023
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut AllergyMatthew Greenhawt, Sayantani B Sindher, Julie Wang, et al.
Allergy|October 30, 2024
EAACI guidelines on the management of IgE-mediated food allergyAlexandra F Santos, Carmen Riggioni, Ioana Agache, et al.
Allergy|October 10, 2023
EAACI guidelines on the diagnosis of IgE-mediated food allergyAlexandra F Santos, Carmen Riggioni, Ioana Agache, et al.
Pageof 26

Showing results (241-250 of 257) with videos related to

Sort By:
Pageof 26
The Journal of Allergy and Clinical Immunology. in Practice|March 1, 2025
Long-Term Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: An Open-Label Active Treatment (REALISE Study)Jacqueline A Pongracic, Rémi Gagnon, Gordon Sussman, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 1, 2021
Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial ResultsJacqueline A Pongracic, Rémi Gagnon, Gordon Sussman, et al.
The Journal of Allergy and Clinical Immunology|July 14, 2020
Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year resultsDavid M Fleischer, Wayne G Shreffler, Dianne E Campbell, et al.
Clinical and Translational Allergy|November 7, 2024
GA<sup>2</sup>LEN ANACARE consensus statement: Potential of omalizumab in food allergy managementTorsten Zuberbier, Antonella Muraro, Ulugbek Nurmatov, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 16, 2025
Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPEMatthew Greenhawt, Deborah Albright, Sara Anvari, et al.
Clinical and Translational Allergy|November 29, 2024
10 practical priorities to prevent and manage serious allergic reactions: GA<sup>2</sup>LEN ANACare and EFA Anaphylaxis ManifestoAntonella Muraro, Debra de Silva, Marcia Podesta, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 21, 2021
The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus ApproachMatthew Greenhawt, Elissa M Abrams, Marcus Shaker, et al.
The New England Journal of Medicine|May 10, 2023
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut AllergyMatthew Greenhawt, Sayantani B Sindher, Julie Wang, et al.
Allergy|October 30, 2024
EAACI guidelines on the management of IgE-mediated food allergyAlexandra F Santos, Carmen Riggioni, Ioana Agache, et al.
Allergy|October 10, 2023
EAACI guidelines on the diagnosis of IgE-mediated food allergyAlexandra F Santos, Carmen Riggioni, Ioana Agache, et al.
Pageof 26